Tradestie Institutional Equity Comparison Engine
EVMN vs DNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EVMN Overall Edge
EVMN Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while DNA counters with relative strength in Momentum & Technical. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus DNA at N/M Forward P/E and -202.5% operating margin (-5.7% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against DNA sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EVMN N/M vs DNA N/M Fwd P/E
Growth & Margin Winner
EVMN
Op Margin 0.0% vs -202.5% ยท YoY +0.0% vs -5.7%
Momentum & Technical Winner
DNA
1Y -61.0% vs +6.2% ยท 52W Pos 8% vs 24%
Options & Structure Winner
EVMN
SURGE (53rd %ile IV) vs BREAKDOWN (34th %ile IV)
EVMN
US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap
$315.5M
1M Return
+37.33%
1Y Return
-61.03%
Forward P/E
N/M
Unified AI Score
30.0 / 100
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
DNA
NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap
$623.0M
1M Return
-17.23%
1Y Return
+6.25%
Forward P/E
N/M
Unified AI Score
56.0 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EVMN -61.03%
DNA +6.25%
Spread: +67.28 pp (DNA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EVMN Revenue | DNA Revenue | EVMN Op. Margin | DNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $50M | N/A | -132.1% | DNA |
| FY2020 | N/A | $80M | N/A | -178.8% | DNA |
| FY2021 | N/A | $310M | N/A | -582.6% | DNA |
| FY2022 | N/A | $480M | N/A | -462.4% | DNA |
| FY2023 | N/A | $250M | N/A | -343.8% | DNA |
| FY2024 | $10M | $230M | -1000.2% | -246.5% | DNA |
| FY2025 | $10M | $170M | -623.6% | -185.3% | DNA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVMN | DNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $315.5M | $623.0M | Larger Scale | DNA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -5.7% | Higher Growth | EVMN |
| Operating Margin (TTM) Profitability | 0.0% | -202.5% | Higher Margin | EVMN |
| Net Profit Margin Profitability | 0.0% | -192.0% | Higher Margin | EVMN |
| Return on Equity (ROE) Capital Efficiency | -69.5% | -58.2% | Higher ROE | DNA |
| 52-Week Range Position Momentum | 8% ($5โ$33) | 24% ($5โ$18) | Stronger Trend | DNA |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 118% Vol | 3.14ฮฒ ยท 152% Vol | Lower Realized Risk | EVMN |
| Unified Institutional Score Composite Signal | 30.0 / 100 (SELL) | 56.0 / 100 (HOLD) | Higher Composite | DNA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EVMN vs DNA Buy Guide
EVMN
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
53rd %ile
IV Regime
Balanced (25thโ60th %ile)
DNA
BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
34th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EVMN nor DNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.